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Abstract
Background: Unaccustomed exercise can result in delayed onset of muscle soreness (DOMS) which can affect
athletic performance. Although DOMS is a useful tool to identify muscle damage and remodelling, prolonged
symptoms of DOMS may be associated with the over-training syndrome. In order to reduce the symptoms of
DOMS numerous management strategies have been attempted with no significant effect on DOMS-associated
cytokines surge. The present study aimed to investigate the acute and chronic effects of a 2 × 180 mg per day
dose of eicosapentaenoic acid (EPA) on interleukin-6 (IL-6) mediated inflammatory response and symptoms
associated with DOMS.
Methods: Seventeen healthy non-smoking females (age 20.4 ± 2.1 years, height 161.2 ± 8.3 cm and mass 61.48 ±
7.4 kg) were randomly assigned to either placebo (N = 10) or EPA (N = 7). Serum IL-6, isometric and isokinetic
(concentric and eccentric) strength, and rating of perceived exertion (RPE) were recorded on four occasions: i-prior
to supplementation, ii-immediately after three weeks of supplementation (basal effects), iii-48 hours following a
single bout of resistance exercise (acute training response effects), and iv-48 hours following the last of a series of
three bouts of resistance exercise (chronic training response effects).
Results: There was only a group difference in the degree of change in circulating IL-6 levels. In fact, relative to the
first baseline, by the third bout of eccentric workout, the EPA group had 103 ± 60% increment in IL-6 levels
whereas the placebo group only had 80 ± 26% incremented IL-6 levels (P = 0.020). We also describe a stable
multiple linear regression model which included measures of strength and not IL-6 as predictors of RPE scale.
Conclusion: The present study suggests that in doubling the standard recommended dose of EPA, whilst this may
still not be beneficial at ameliorating the symptoms of DOMS, it counter intuitively appears to enhance the
cytokine response to exercise. In a context where previous in vitro work has shown EPA to decrease the effects of
inflammatory cytokines, it may in fact be that the doses required in vivo is much larger than current
recommended amounts. An attempt to dampen the exercise-induced cytokine flux in fact results in an over-
compensatory response of this system.
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Introduction
Although exercise is generally shown to be beneficial, a
bout of resistance exercise that an individual is unaccus-
tomed to can result in a reduction in force generating
capacity (RFGC) and post-exercise muscle soreness,
commonly known as Delayed Onset Muscle Soreness or
DOMS [1,2]. There is no known definitive cause of
DOMS, although Lenn et al. [3] suggested that there are
two concurrent mechanisms responsible. The initial
mechanism for muscle damage occurs following unac-
customed exercise (predominantly eccentric contrac-
tions). The damage to muscle fibres ranges from
alterations to a small number of macromolecules to
large tears in the sarcolemma, basal lamina and in the
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surrounding connective tissue [4,5]. Following damage
to skeletal muscle the secondary mechanism is a loss of
intramuscular protein and the release of growth factors
that modulate satellite cells activity, which begin the
repair and regenerative process [4,5], as well as involving
the production of biochemical end products including
cytokines. Asmussen [6] indicated that these biochem-
ical end products may affect nerve endings and activate
nociceptors creating the sensation of muscle soreness.
The functional impact of this muscle soreness was
addressed by Graven-Nielsen et al. [7], who demon-
strated that those experiencing muscle pain were unable
to achieve maximum voluntary contractions (MVCs).
The structural damage to the contractile proteins and
membranes within skeletal muscle signals the hypothala-
mic pituitary adrenal axis (HPA) to produce acute phase
proteins in, and around, the damaged site. The produc-
tion of acute phase proteins includes the production of
cytokines, specifically those that initiate the incursion of
lymphocytes, neutrophils and monocytes, which insti-
gates the healing phase, thereby emphasising the impor-
tance of the cytokines produced [8,9]. Some of the
cytokines produced include tumour necrosis factor
alpha (TNF-a), interleukin-1 (IL-1), interleukin-6 (IL-6)
and interleukin-10 (IL-10) [9]. These cytokines have
been identified as pro-inflammatory cytokines due to
the similarities with responses to trauma and infection
when injected into humans [10]. IL-6 in particular, has
been suggested to possess both pro - and anti-inflamma-
tory properties and is therefore generally referred to as
an inflammation responsive cytokine [11,12].
Northoff et al. [13] suggested that increases in IL-6
may be involved in the generation of acute phase
inflammation post exercise. To date, research indicates
that the substantially increased IL-6 both during and
post resistance exercise, may be dependent on the inten-
sity and nature of muscular contraction [2,14]. Similarly,
Pedersen et al. [14] suggested that the level of DOMS
experienced is linked to the quantity of IL-6 produced.
Interestingly, the work of Pedersen et al. [14], and
further research by Richards et al. [11] suggest that the
IL-6 response experienced post exercise, may not be
entirely beneficial nor necessary for muscle develop-
ment. This has led to research on the effects of exces-
sive levels of IL-6 both in vivo and in vitro. Bauman et
al. [15] and Febbraio et al. [16] linked excessive levels of
IL-6 to cancer and chronic inflammation in elderly indi-
viduals. Possible underlying mechanisms include a dele-
terious positive feedback loop of the hypothalamic-
pituitary adrenal (HPA) axis and an increase in C-reac-
tive protein (CRP) production. Yet, in contrast to afore-
mentioned studies, Al-Shanti et al. [17] demonstrated in
vitro that IL-6 in combination with TNF-a, promoted
myoblast cell proliferation. Therefore, IL-6 appears to
have both positive and negative effects associated with
muscle repair and regeneration. It is unclear, however,
at what point IL-6 levels may become detrimental. If an
elevated IL-6 response in muscle damage is not essential
for muscle development, then a reduction in IL-6 may
positively impact recovery time from exercise, whilst
simultaneously optimising performance. There is suffi-
cient evidence to suggest that the cytokines produced
post muscle damage are linked to DOMS [2,11,13,14].
Consequently in an attempt to reduce the cytokine
response and DOMS following muscle damage, numer-
ous management modalities such as massage, cryother-
apy, stretching and ibuprofen have been tried though
the evidence regarding either their benefit or otherwise
is still not conclusive [3].
There is evidence to suggest that dietary supplements
such as omega-3 containing fish-oil, specifically the
polyunsaturated fatty acid 20:5n3 component (also com-
monly known as eicosapentaenoic acid or EPA), may be
efficient at reducing the pro-inflammatory cytokines
associated with inflammation [18,19]. Magee et al. [18]
demonstrated in vitro that EPA inhibited the effects of
TNF-a by reducing its apoptotic effects and enabling
myogenesis, thus allowing optimal skeletal muscle cell
differentiation from myoblasts into myotubes, a process
which is key in the regeneration of muscle following
damage. Complimentary evidence was provided in vivo
by Matsuyama et al. [19] who worked with patients suf-
fering from chronic obstructive pulmonary disease
(COPD). COPD is characterised by chronic inflamma-
tion and pain in the throat and chest when breathing.
Matsuyama et al. [19] treated patients for 24 months
with EPA supplementation. With treatment, participants
exhibited lower TNF-a levels and reported a reduction
pain in comparison with baseline values. The findings
from these two studies suggest a link between elevated
levels of pro-inflammatory cytokines and pain [6] and
also that EPA may be beneficial in reducing the symp-
toms of DOMS and the level of inflammation associated
with it.
In this potential therapeutic context, several studies
have already queried whether omega-3/EPA doses
between 300 mg/day to 2224 mg/day can affect the
acute inflammation response and symptoms associated
with DOMS after a single bout of exercise [3,20,21].
Lenn et al. [3], using 1800 mg/day of omega-3, reported
that EPA had no effect on range of motion, pain, IL-6,
TNF-a and creatine kinase levels. However, Phillips et
al. [20] (using a daily cocktail of 300 mg of tocopherols
plus 800 mg of docosahexaenoate plus 300 mg of flavo-
noids) and Bloomer et al. [21] (using 2224 mg/day of
EPA) both reported a reduction in IL-6, CRP and TNF-
a respectively, following a single bout of exercise. These
studies in conjunction with the in vivo and in vitro work
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mentioned earlier [18,19] exemplify the confusion as to
whether EPA may be beneficial in reducing pro-inflam-
matory cytokines linked with the inflammatory response
and the symptoms associated with DOMS. To date the
impact of fish oils on the acute and chronic response to
a single bout of exercise remains unclear. Moreover, the
conventional dose of 1000-2000 mg per day (of total
fish oil or 180-360 of EPA) has mainly been far
exceeded in the research to date.
Aims and Objectives
The aims of the present study were therefore to investi-
gate the effects of a dose of EPA supplementation just
above standard recommendations, on basal inflamma-
tion, as well on both the acute and the chronic resis-
tance exercise responses. It was hypothesised that not
only could basal inflammation be decreased with EPA,
but also that, despite a protocol designed to maximise
potential DOMS, self-reported muscle soreness would
decrease, circulating cytokine levels would be minimised,
and muscle strength would be enhanced in the presence
of EPA directly as a result of the creation of a more
hospitable environment for muscle recovery.
Materials and methods
Pilot Study
A pilot study was conducted prior to testing to deter-
mine optimal joint angle and speed of contraction for
maximal voluntary contractile efforts, whilst also testing
for test-retest reliability both within and between ses-
sions for quadriceps and hamstrings strength measure-
ments. The pilot study revealed that the optimal angle
and velocity for peak torque were 65° and 180°·s-1
respectively for the selected population.
Participants
A word-of-mouth advertising campaign was run within
the local university campus. Forty convenience-sampled,
non-smoking female university students responded to the
call for participants. A further inclusion criterion was for
participants to be currently taking progestin-only contra-
ceptive pills and to be sedentary, in order to minimise the
impact of intrinsic hormonal levels differences and/or var-
iations in the habitual physical performance of the partici-
pants [22-24]. Other inclusion criteria were for
participants to be naïve to resistance exercise, free from
asthma, non-users of any vitamin/mineral supplementa-
tion (for at least two weeks prior to baseline). Participants
also had to agree to maintain their habitual activity levels
and to not commence a weight loss programme for the
duration of the study (i.e. ~6 weeks). Exclusion criteria
included drugs or alcohol abuse (two weeks prior to base-
line), bacterial infection (two weeks prior to baseline),
musculo-skeletal injury in the six months (preceding
baseline) and use of anti-inflammatory and/or steroid
medication (four weeks prior to baseline). Of the forty
convenience sample twenty of the respondents (age 20.4 ±
2.1 years, body height 161.2 ± 8.3 cm and mass 61.48 ±
7.4 kg) fulfilled the inclusion criteria. All selected partici-
pants signed an informed consent form, approved by the
local university ethics committee, prior to their inclusion
in this study.
Study Design
The study was a nine-week, double-blind placebo con-
trolled design using the dietary supplement EPA versus
lecithin as placebo. Participants were randomly allocated
to receive either the EPA (N = 10) or the placebo (N =
10) supplementation for three weeks between baseline
one (B1) and baseline two (B2). Participants were famil-
iarised to all gymnasium and laboratory proceedings
prior to B1. A week before B1 all participants were
taken to the gym where one repetition maxima (1RM)
were tested for the programmed exercises. Fasting
venous blood samples, rating of perceived exertion
(RPE), isometric and isokinetic strength assessments
were then taken on four separate occasions including B1
(baseline 1), B2 (i.e. baseline 2 which occurred three
weeks after baseline 1; B1 and B2 sessions were sepa-
rated by three weeks of supplementation/placebo), S1 (i.
e. resistance training session 1 which occurred post B2;
here, one week after B2 participants performed a single
bout of resistance training and were tested 48 hours
after this bout of exercise), and finally S3 (i.e. resistance
training session 3 which occurred after S1; here, upon
completion of three weeks of weekly eccentric resistance
training (including S1) participants were tested 48 hours
after the final training session).
Three participants did not complete the entire experi-
mental protocol resulting in data presented for EPA (N
= 7) and placebo (N = 10). Participants were tested in
the afternoon within the same two-hour window each
day to minimise any impact of the circadian rhythm on
the physical capacities of the participants [25].
Supplementation
EPA supplementation was two 1000 mg softgel caps of
omega-3, containing in total for the 2 gels 360 mg of
EPA (18%) (MyProtein, Manchester, UK). This is twice
the minimum dose as recommended by the American
Heart Association. The placebo group received two
1000 mg softgel caps of lecithin (MyProtein, Manche-
ster, UK). Participants were asked to take the capsules
daily with a meal.
Training Programme
Training intervention took place between 14:00 - 18:00
in an attempt to ensure optimal muscle performance
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[26,27] and thus potentially maximise DOMS. Upon
completion of appropriate warm up, participants com-
pleted four exercises (See Figure 1) including walking
lunges (with free weights), straight leg dead lifts (with
free weights), leg extension (with a leg-extension
machine; Pulse 562E class ‘s’ 8/88. Pulse-fitness, Congle-
ton, England), and leg flexion (with a leg flexion
machine; Pulse 562E class ‘s’ 8/88. Pulse-fitness, Congle-
ton, England). Participants 1RM was pre-determined at
the beginning of each training session, after which parti-
cipants completed three sets of ten repetitions once a
week working at 70% of their pre-determined 1RM over
45 minutes. Each repetition was completed within six
seconds including concentric, isometric and eccentric
phases. With regards to the progression of loading dur-
ing training, for all three resistance training sessions (i.e.
at S1, one week after S1 and at S3) participants’ 1RM
(for each of the four exercises) was determined at the
beginning of the session. Participants then worked at
70% of the newly determined 1RM, thereby ensuring a
load progression relative to the preceding training ses-
sion. Thus, overall, each training session lasted 60 min-
utes including 1RM assessments and 3 sets of 10
repetitions of each of four exercises. This was similar to
a protocol used elsewhere in previous research [28],
designed to ensure muscle damage would occur.
Strength Assessment
Maximal isometric and isokinetic (concentric and
eccentric) knee extension were measured on the right
leg for all participants. Measurements were assessed at
65°, and 180°·s-1 as these were optimal knee angle and
velocity for peak torque as demonstrated during the
pilot study (full knee extension = 0°). Participants were
seated on the isokinetic dynamometer (Cybex; Phoenix
Healthcare Products, Nottingham, UK), which was cali-
brated prior to testing. The right knee was positioned
so that the epicondylus laterallis was aligned to the
centre of rotation of the motor arm. Straps were then
positioned across the shoulder/chest, and over the
right thigh to prevent any extraneous movement. Force
application against the lever arm of the dynamometer
was carried out with placement of the appropriate
attachment set at a relative 80% of the lower leg length
distally from the lateral condyle of the tibia. Partici-
pants were permitted a warm-up, which included five
sub-maximal repetitions of knee flexions and exten-
sions of the right limb at 100°·s. Testing included three
trials, with 2 minutes rest between efforts, for both iso-
metric and isokinetic conditions with peak knee exten-
sion torque used as the participant’s strength score.
Both visual and auditory feedback were used to encou-
rage maximal efforts.
Blood Collection and IL-6 detection
Participants fasted for eight hours prior to blood sam-
ples being taken from the anticubital vein of the forearm
by a trained phlebotomist using a 21 ml gauge needle
(S-Monovette, Sarstedt, Germany). Five millimetres of
blood were taken and allowed to clot whilst standing for
one hour on ice. The samples were then centrifuged
(Hermle Z 380, Huddersfield) in 5°C at 4000 RPM for
10 minutes to separate the serum from the blood cells.
Two aliquots (~900 μl each) of the resulting sera sam-
ples were taken and stored at -20°C for later analysis.
IL-6 (R&D Systems inc. Minneapolis, USA. Sensitivity <
0.7 pg/ml; Intra-assay variability of 2.6%) concentrations
were quantified using a standard ELISA (enzyme linked
immuno sorbant assays) procedure.
Statistical Analyses
Data were analysed using the Statistical Package for the
Social Sciences (SPSS, Chicago, IL) version 18. The data
on strength, IL-6 levels and changes in circulating IL-6
relative to baseline fulfilled the criteria for parametricity.
IL-6 levels and relative changes (i.e. T1 = B2-B1/B1, T2
= S1-B1/B1 and T3 = S3-B1/B1) as well as strength data
were analysed using a mixed design repeated measures
two-way analysis of variance (ANOVA). The ‘Within’
factor was the protocol phase which had four levels (B1,
B2, S1 and S3) and the ‘between’ factor was the treat-
ment group with two levels (EPA treated vs. placebo).
Post hoc tests were conducted with appropriate Bonfer-
onni corrections. RPE data, as it was non parametric,
was analysed within groups using a Friedman’s test, fol-
lowed by Wilcoxon signed-rank post-hoc tests. Between
groups comparisons of RPE data were run using the
Figure 1 Resistance exercise, A - leg flexion, B - leg extension,
C - straight leg dead lifts, D - walking lunges (Authorised use
of photos from a study participant, personal communication,
April 26 2010).
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Kruskal-Wallis test with Mann-Whitney post-hoc com-
parisons. An ANCOVA test (with Greenhouse-Geisser
adjustments for non-equal variance) was used to evalu-
ate whether the statistical significance of the changes in
IL-6 since IL-6 levels were heterogeneous between
groups at baseline (i.e. an unpaired student t-test
showed that IL-6 in EPA and Placebo groups was signif-
icantly different at B1, P = 0.012). Evaluation of any
association between IL-6, strength measurements (iso-
metric and isokinetic) and RPE Borg pain scale were
analysed using correlations and a multiple linear regres-
sion. Data are presented as mean ± standard error of
the mean (SEM). Differences were considered significant
at an alpha level of 0.05 (i.e. P ≤ 0.05).
Results
Mean coefficient of variance (CV) for repeated measure-
ments (intra-day variability) ranged between 1.0-2.0%
and 0.8-2.7% on days one and two respectively for iso-
metric measurements. The intra-day CV for the isoki-
netic measurements ranged from 1.3-1.9% and 1.4-2.7%
on days one and two respectively. The inter-day CVs for
repeated measurements ranged between 1.5-1.75% for
isometric measurements, and 1.6-2.1% for isokinetic
measurements.
Isometric Strength
There was a reduction in torque (see Figure 2A) of
13% (P = 0.007) between B1 (EPA 219 ± 34 Nm; pla-
cebo 211 ± 36 Nm) and S1 (EPA 195 ± 46 Nm; pla-
cebo 181 ± 23 Nm), and a 14% (P = 0.004) reduction
in torque between B2 (EPA 219 ± 36 Nm; placebo 212
± 35 Nm) and S1 (EPA 195 ± 46 Nm; placebo 181 ±
23 Nm). However, there was a 15% (P = 0.001)
increase in the torque generated between S1 (EPA 195
± 46 Nm; placebo 181 ± 23 Nm) and S3 (EPA 223 ±
32 Nm; placebo 211 ± 39 Nm) for grouped data. The
main effect for groups shows that when all of the iso-
metric strength for the EPA group was compared with
the placebo group (EPA 214 ± 12 Nm vs. placebo 204
± 15 Nm), they were not significantly different (P >
0.05). Thus, no interaction existed between treatment
and time (P > 0.05).
Concentric & Eccentric Torque
With concentric torque (see Figure 2B), there was a
main effect of time for pooled data between B1 (100 ±
32 Nm) and S1 (94 ± 30 Nm) P = 0.008, B2 (101 ± 31
Nm) and S1 (94 ± 30 Nm) P = 0.018 and S1 (94 ± 30
Nm) and S3 (110 ± 34 Nm) P = 0.001. There was how-
ever no main effect of group (EPA 116 ± 7 Nm vs. pla-
cebo 91 ± 9 Nm, P > 0.05). There was no interaction
between treatment and time in terms of concentric
strength data (P > 0.05).
Similarly for eccentric torque (see Figure 2C), there
was a main effect of time for pooled data between B1
(205 ± 65 Nm) and S1 (167 ± 63 Nm) P = 0.001, B2
(206 ± 64 Nm) and S1 (167 ± 63 Nm) P = 0.001 and S1
(94 ± 30 Nm) and S3 (222 ± 78 Nm) P = 0.001, but not
for group (EPA 236 ± 22 Nm vs. placebo 174 ± 19 Nm,
P > 0.05). There was thus no interaction between treat-
ment and time in terms of eccentric strength (P > 0.05).
Muscle Soreness
There was no change in background pain scores (See
Figure 2D) between the two baselines (B1 = 6.00 ± 0.00
and B2 = 6.00 ± 0.00, P > 0.05). Throughout the experi-
mental phase, there was a non-significant trend for the
placebo to demonstrate slightly larger ratings of per-
ceived exertion (B1 = 6.00 ± 0.00, B2 = 6.00 ± 0.00, S1
= 16.62 ± 1.35 and S3 = 12.01 ± 1.25; P > 0.05) in com-
parison with the EPA group (B1 = 6.00 ± 0.00, B2 =
6.00 ± 0.00, S1 = 16.02 ± 0.82, S3 = 11.80 ± 1.11; P >
0.05).
Cytokines
In the analysis of the IL-6 data (See Figure 3), since the
study population was heterogeneous at baseline, this
baseline difference therefore had to be partialled out.
After accounting for the baseline differences in IL-6
levels, there was not only a main effect of time (i.e.
experimental phase) on circulating IL-6 levels (P =
0.002), but there was also an interaction between time
(B1, B2, S1, S3) and group (EPA vs. Placebo). In fact,
the IL-6 levels in the EPA group, even after adjusting
for baseline differences, were more augmented with
exercise compared with levels in the absence of this
treatment (relative to B1, the increments at S3 were 80
± 26% in the placebo group, and 103 ± 60% in the EPA
group; P = 0.020).
Evaluation of bivariate associations
At day one (i.e. B1) and day twenty-one (i.e. B2), there
were significant associations between isometric,
eccentric and concentric strength only (r = 0.668 (iso-
metric vs. concentric), r = 0.635 (isometric vs.
eccentric), r = 0.802 (concentric vs. eccentric); p < 0.01
at B1 and (r = 0.688, r = 0.624, r = 0.790; p < 0.01) at
B2). IL-6 level was not associated with any strength
measure. RPE was constant across the population so no
association could be computed. At days twenty-three (i.
e. S1) and forty-four (i.e. S3), there was still a significant
association between isometric, eccentric and concentric
strength (r = 0.752, r = 0.819, r = 0.845; p < 0.001 at S1;
r = 0.861, r = 0.797, r = 0.901; p < 0.001 at S3). IL-6
level was still not associated with any strength measure
(P > 0.05). RPE, though now varying between partici-
pants, still showed no association either with strength
measures or IL-6 levels (P > 0.05).
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In addition, when a multiple linear regression was run
on the pooled data with RPE scale as the dependent
variable and IL-6, isometric/concentric/eccentric
strength measures as independent variables, it was
found that the stable model for predicting RPE scale (as
the common indicator of DOMS) reads as, RPE scale =
(-0.044 × isometric strength) + (0.137 × concentric
strength) + (-0.049 × eccentric strength) + 4.074, r =
0.451, p = 0.002. Indeed IL-6 was not a good predictor
of RPE scale.
Discussion
Evidence from clinical and experimental studies suggests
that omega-3 has a protective effect against cancer-
induced cachexia, ageing-related chronic inflammation
and other inflammatory diseases associated with exces-
sive levels of cytokines [17]. This has led to further
research to investigate whether EPA can have the same
positive response on pro-inflammatory cytokines and
symptoms associated with DOMS following exercise.
Phillips et al. [20] and Bloomer et al. [21] both provided
evidence to support the earlier in vivo and in vitro work
[18,19], although both studies only observed the initial
acute response after a single bout of exercise. These stu-
dies provided the basis for the current study in an
attempt to observe if a dose of EPA which is twice the
daily recommended level (i.e. ~2 × 180 mg per day)
would inhibit acute and chronic IL-6 mediated inflam-
mation, muscle soreness and RFGC following resistance
exercise. The findings from the present study suggest
that after three weeks of treatment, the standard dose of
EPA may not be beneficial in ameliorating the symp-
toms associated with DOMS and IL-6 mediated inflam-
mation response to exercise. In fact, the data would
suggest that whereas strength and pain sensations
related to resistance exercise are no different with/
Figure 2 EPA and placebo group changes in isometric (A) concentric (B) eccentric torque (C) and RPE pain scale (D) at B1 (1st
baseline), B2 (2nd baseline i.e. after three weeks of supplementation), S1 (after one bout of eccentric exercises) and S3 (after three
bouts of eccentric exercises). Data are mean ± SEM. * indicates significant difference (P ≤ 0.05).
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without EPA, exercise-induced IL-6 levels are in fact sig-
nificantly elevated following three weeks of daily intake
of EPA.
Babcock et al. [29] previously suggested two possible
mechanisms that may be responsible for the anti-inflam-
matory ability of EPA. An initial response is for the EPA
to be readily incorporated into the cellular membrane,
where it alters linolenic and linoleic acids, which are
essential for the production of arachidonic acid, the lat-
ter which is in fact involved in pain and inflammation.
This was based on the earlier findings of Endres et al.
[30], who looked at inflammation at a more cellular
level in humans and rodents. They demonstrated that
once within the cellular membrane, inflammation is
affected by reducing prostaglandin E2 (PGE2) levels.
Additionally a further mechanism was demonstrated by
Lo et al. [31], who indicated that EPA modulates inflam-
mation at a molecular level by down regulating the ubi-
quitin-proteasome proteolytic pathway, through
decreasing translocation of nuclear factor-b (NFb).
The authors indicated that EPA possesses the ability to
reduce NFb, which is involved in protein degradation.
A reduction in NFb would enable a positive environ-
ment for protein synthesis for repair of muscle following
exercise, rather than a catabolic one. These are only two
of the possible mechanisms by which EPA may alter
levels of inflammation, however if effective then indivi-
duals in a clinical or sporting context may benefit. If
either is effective at reducing inflammation associated
with muscle damage, then it may be reasonable to
assume that IL-6 mediated inflammation and DOMS
would be reduced in the EPA group. However, the find-
ings from the present study do not support this
hypothesis.
DOMS post exercise is associated with RFGC, [7]
muscle soreness [3] and elevated levels of cytokines [13].
The protocol used in the present study was designed to
initiate an IL-6 mediated inflammatory response, muscle
soreness and a RFGC, to demonstrate DOMS was
achieved. Participants’ pain was assessed 48 h post resis-
tance exercise, and in accordance with previous research
[3,20] muscle soreness did not alter between B1 and B2,
however it did increase from B2 by 64% and 50% to S1
and S3 respectively (See Figure 2D). Participant’s maxi-
mal isometric force ability decreased 48 h post resis-
tance exercise by ~14% between B1 and S1, and B2 and
S1. The reduction in participant’s ability to generate
force highlighted in the present study post resistance
exercise is in accordance with previous research [2,16].
This reduction in participant’s ability to generate force
was matched by an increase in pain, which is in agree-
ment with the work of Graven-Nielsen et al. [7]. The
initial force reducing capacity of the muscles was evi-
dent in all three forms of contractions; however both
forms of isokinetic contractions (concentric and
eccentric) reported an increase between B1 and S3. A
possible explanation for poor development in muscle
force generating capacity for isometric contractions may
have been due to the difference between the angles
achieved when exercising compared to those used when
strength assessments were carried out. When assessing
muscle force generating capacity for isometric contrac-
tions the angle was set at 65°, however when performing
resistance exercise this angle may have only been briefly
achieved during the leg extension/flexion exercise (See
Figure 1A and 1B). Morrissey et al. [32] reported an
increase in motor unit activation at specified angles
when working isometrically, therefore if the legs were
not trained specifically at 65° degrees then there will be
no increase in force generating capacity at that specific
angle.
There was an increase in IL-6 48 h post resistance
exercise of 26% and 43% between B1 and S1 and B1 and
S3 respectively for grouped data. In addition there were
also increases in IL-6 of 22% and 40% for grouped data
between B2 and S1, and B2 and S3 respectively. These
alterations in IL-6 are consistent with previous research
demonstrating increases in IL-6 following an exercise
protocol aimed at maximising DOMS (See Figure 3)
[9,20]. The above support the assertion that the protocol
used in the present study was effective at initiating
DOMS.
In accordance with previous research eccentric con-
tractions were included using a large muscle mass to
maximise the IL-6 response [33]. Both EPA and placebo
Figure 3 Changes in IL-6 mediated inflammation for EPA and
placebo groups for B1 (1st baseline), B2 (2nd baseline i.e. after
three weeks of supplementation), S1 (after one bout of
eccentric exercises) and S3 (after three bouts of weekly
eccentric exercises). * indicates a significant difference (P ≤ 0.05). A
repeated measures ANCOVA shows a significant (P = 0.002) main
effect of time (differences between B1 to S1, and B1 to S3) as well
as an interaction between time and group (P = 0.020). Data are
mean ± SEM.
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groups had an increase in IL-6, in agreement with pre-
vious research [2]; however, the increment in the EPA
group was significantly greater than that in the placebo
group.
Our findings of elevated IL-6 post-exercise contradict
the previous research of Phillips et al. [20] and Bloomer
et al. [21], who demonstrated a reduction in cytokines
IL-6 and TNF-a 48 h post exercise. It should however
be noted that Phillips et al. [20] used a combination of
EPA, docasahexaenoate (DHA), tocopherols and flavo-
noids, and Bloomer et al. [21] used EPA and DHA in
the supplement groups. This therefore raises the ques-
tion of whether it was this combination of fish oils, or
whether it was EPA, DHA, tocopherols or flavonoids,
which were individually responsible for the reduction in
IL-6, TNF-a and CRP. The variability of the fish oil
used may be a possible explanation for the discrepancy
between the findings of Phillips et al. [20] and Bloomer
et al. [21] and the findings of the present study.
As mentioned above, the IL-6 response post exercise
appears to be associated with greater generated torques
[14] and muscle soreness post resistance exercise [3].
Notwithstanding the data from Lenn et al. [3] it is
unclear whether there is a direct link between IL-6 and
muscle soreness experienced post resistance exercise.
The work of Graven-Nielsen et al. [7] demonstrated that
muscle soreness significantly reduces MVC, possibly due
to cytokines, such as IL-6 affecting nerve endings and
activating nocieoceptors [6]. Therefore if IL-6 is asso-
ciated with pain, then any reduction in IL-6 through
EPA supplementation should be reflected in a reduction
in pain. This, however, was not the case in the present
study. In fact, our data show no association between IL-
6 and any of the generally accepted markers of DOMS.
The lack of any clear link between IL-6 and pain sensa-
tion is evidenced in data provided by Phillips et al. [20]
which suggests that whilst a fish oil-treated group had a
significantly reduced IL-6 level 72 h post exercise, this
was not matched with a reduction in perceived pain.
The data provided both here and in Phillips et al. [20]
suggest that IL-6 may not be involved in the muscle
soreness experienced post resistance exercise, and that
other pro-inflammatory cytokines such as TNF-a or IL-
1b may be responsible, however this was beyond the
scope of the current study to determine and requires
further research.
The data from the present study agrees with the find-
ings from Lenn et al. [3], who suggested that EPA may
not be beneficial at ameliorating the effects of DOMS
and reducing levels of IL-6. However, this may have
been due to any factor from insufficient work done to
initiate a cytokine response (these authors trained a rela-
tively small muscle mass (biceps brachii) and reported
no increase in IL-6 post-exercise [14]), to the timing of
blood sampling (24 h instead of 48 h post exercise [14]),
or indeed EPA dosage (these authors did not specify the
amount of EPA given to study participants), or a combi-
nation of both.
Although diet standardisation is notoriously difficult
to monitor [34] this would allow researchers to truly
assess the impact of EPA. Caughey et al. [35] ran a
study involving four weeks of a diet high in cooking oils
and spreads, followed by four weeks of fish oil capsules
(a daily intake of 1620 mg of EPA (i.e. 78% more than
the dose used in the present study) and 1080 mg of
DHA). The authors reported significantly inhibited basal
TNF-a and IL-1b synthesis.
In the current study blood samples were taken 48 h
post resistance exercise however, both conflicting and
supporting evidence exists for peak release of IL-6 dur-
ing this time period. Hellsten et al. [36] used a proto-
col similar to that of the present study with blood
samples ranging from one to 96 h post exercise. The
authors suggested that the prolonged release of IL-6
may be due to the increase in cellular xanthine oxidase
activity. Furthermore, Pedersen et al. [14] indicated
that IL-6 acts as an intracellular signaller for leuco-
cytes, such as neutrophils, which migrate towards che-
moattractants, such as IL-6. These neutrophils then
accumulate at the site of muscle damage, where the
lifespan is between 24-48 h, suggesting a possible
explanation for peak IL-6 48 h post exercise. Yet evi-
dence to the contrary of the two aforementioned
authors was provided by Croisier et al. [8] and Steens-
berg et al. [37]. Both studies indicated that IL-6 peaks
within the first 30 minutes to six hours post exercise,
prior to returning to baseline values. Peak IL-6 levels
were reported by Croisier et al. [8] and Steensberg et
al. [37] as 10 pg/ml and 8 ng/l, respectively. Both stu-
dies used protocols similar to that of the present
study, although the peak levels of IL-6 were not con-
sistent with the present study of 4.6 pg/ml. It should
be pointed out here that Steensberg et al. [37] took
muscle biopsies, therefore a direct comparison with
the present study cannot be made. Steensberg et al.
[37] indicated that the main function of the early
release of IL-6 is to operate in a ‘hormone-like man-
ner ’ and play a role in carbohydrate metabolism,
through activating extramuscular substrates and sup-
plementing substrate delivery during and post resis-
tance exercise. Furthermore, this hormone-like
behaviour of IL-6 stimulates the hypothalamic pituitary
axis (HPA) axis, and in doing so contributes to the
inflammatory response post exercise. Moreover Al-
Shanti et al. [17] demonstrated that early release of IL-
6 has beneficial effects on skeletal muscle cells since
adding IL-6 to myoblasts enhanced cell proliferation in
a linear fashion, with peak cell count occurring within
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the first 24 h. Supporting the work of Steensberg et al.
[37], Febbario et al. [16] suggested that the early
release of IL-6 is involved in hepatic glucose metabo-
lism, as IL-6 has been shown to inhibit glycogen
synthase activity and accelerate glycogen phosphorylase
activity. These findings suggest that IL-6 is involved in
mediating blood glucose homeostasis, when skeletal
muscle increases its uptake of blood glucose.
In the present study, despite being non-significant,
the EPA group had a greater increase in isometric and
isokinetic eccentric torque generation between B2 and
S3 compared to the placebo group (2.23 and 10%, 0
and 6%, respectively), and these were associated with
greater IL-6 levels increases compared with the pla-
cebo group. These findings could provide some indir-
ect support to the in-vitro work of Al-Shanti et al. [16]
and the in-vivo research of Xing et al. [12], who
reported that IL-6 is beneficial in promoting muscle
growth and repair, and is essential for controlling local
and systemic inflammatory response. Therefore it is
possible that the elevated levels of IL-6 in the EPA
group may have been linked to a relatively enhanced
muscle contractile capacity (as shown through higher
strength increments), resulting in greater glycogen
depletion, which would then cause an increase in glu-
cose metabolism as well as an increase in circulating
IL-6 levels. Whatever the case, the underlying mechan-
ism of how EPA impacts on the production of IL-6 is
unclear and requires further research.
Conclusion
Based on the protocol used in the present study the data
suggests that a 360 mg daily intake of EPA over three
weeks may not be beneficial in reducing DOMS or IL-6
mediated inflammation, at least not in the way we
would have expected it to. In fact it would appear that
this dose enhances the exercise-induced cytokines surge
by a factor of ~20%.
Further research may include varying levels of EPA
supplementation, as Babcock et al. [29] suggests there
may be a dose-response relationship of EPA on the inhi-
biting effect on IL-6 production. In addition it may be
interesting to observe other pro-inflammatory cytokines
such as IL-1, IL-8 and TNF-a as indicators of inflamma-
tion caused by muscle damage, and the interactions if
any, that EPA may have with them. Furthermore the
present findings suggest that the temporal expression of
IL-6 requires further investigation.
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